Clinical Center Reference Endotoxin

Phase 1Biologic

UUniversity of North Carolina, Chapel Hill

Clinical Center Reference Endotoxin is one of 63 biologic programs targeting Allergic Asthma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Allergic AsthmaActive, not recruiting

AsthmaActive, not recruiting

Allergic AsthmaPhase 1

Active, not recruiting

AsthmaPhase 1

Active, not recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

Veramyst

GSK

Preclinical

46 2

Singulair

AstraZeneca

Preclinical

17 3

Nucala

GGlaxo Dba Glaxosmithkline

Preclinical

35 4

Asmanex

Novartis

Preclinical

5 5

Celexa

AbbVie

Preclinical

1 6

Spiriva

Boehringer Ingelheim

Preclinical

8 7

Qvar

Chiesi Farmaceutici S.p.A.

Preclinical

8 8

Atrovent

Boehringer Ingelheim

Preclinical

5 9

Formoterol Fumarate

AstraZeneca

Preclinical

8 10

Symbicort

AstraZeneca

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Asthma2 trials

Safety Study of 20,000 EU of Clinical Center Reference Endotoxin in Allergic Adults With and Without Mild Asthma

Terminated·UUniversity of North Carolina, Chapel Hill·Phase 1·NCT00630461·4 enrolled

Effect of a 10,000 EU Dose of Endotoxin in Allergic and Mildly Asthmatic Adults

Completed·UUniversity of North Carolina, Chapel Hill·Phase 1·NCT00839189·11 enrolled

Adult1 trial

Response of Airway Cells to 20,000 EU of Endotoxin in Normal Adults

Terminated·UUniversity of North Carolina, Chapel Hill·Phase 1·NCT00838851·26 enrolled

Allergic Asthma1 trial

A Study of Inhalation of 20,000 EU CCRE in Normal Volunteers Compared to Allergic Asthmatic Individuals

Completed·UUniversity of North Carolina, Chapel Hill·Phase 1·NCT00839124·32 enrolled

Heart1 trial

Effects of 20,000 EU of Clinical Center Reference Endotoxin (CCRE) Versus Placebo(ENDOHEART)

Completed·UUniversity of North Carolina, Chapel Hill·Phase 1·NCT03623022·15 enrolled

Unspecified1 trial

Inhalation of 20,000 Endotoxin Units(EU) of Clinical Center Reference Endotoxin in Healthy Volunteers

Completed·UUniversity of North Carolina, Chapel Hill·Phase 1·NCT00654134·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Clinical Center Reference Endotoxin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Clinical Center Reference Endotoxin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Clinical Center Reference Endotoxin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of North Carolina, Chapel Hill company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: UUniversity of North Carolina, Chapel Hill

Clinical Center Reference Endotoxin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Asthma2 trials

Adult1 trial

Allergic Asthma1 trial

Heart1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News